OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION

GHENT, Belgium, July 14, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it has received a notification of shareholdings from Oppenheimer Funds, Inc. (OFI).

Oppenheimer Funds, Inc. (OFI) notified Ablynx that they have exceeded the 3% threshold and now hold 1,672,262 Ablynx shares, which represent 3.07% of the current 54,407,572 outstanding shares of Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck Serono, Novartis and Taisho Pharmaceutical Co., Ltd. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx: Dr Edwin Moses CEO t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  [email protected]

Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  [email protected] Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications: Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville t:   +44 203 709 5700 e:  [email protected]

HUG#1937750

You May Also Be Interested In

• Bucked Up® Launches Hunt: Orange Cream, a Limited-Edition Flavor Built to Fuel Your Hunt
• Michael Bogdan Scholarship for Healthcare Opens 2027 Application Cycle for Future Medical Professionals
• Johnny Blue Skies & The Dark Clouds Bring Mutiny For The Masses Tour to nugs with Exclusive Livestreams and Official Concert Audio